Cargando…

NAFLD/MAFLD: New Evidence

Detalles Bibliográficos
Autores principales:	Mantovani, Alessandro, Dalbeni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138393/ https://www.ncbi.nlm.nih.gov/pubmed/37108404 http://dx.doi.org/10.3390/ijms24087241

Ejemplares similares

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Recent Developments in NAFLD
por: Mantovani, Alessandro, et al.
Publicado: (2022)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Treatments for NAFLD: State of Art
por: Mantovani, Alessandro, et al.
Publicado: (2021)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

MAFLD and NAFLD in the prediction of incident chronic kidney disease
por: Kwon, So Yoon, et al.
Publicado: (2023)

The NAFLD–MAFLD debate through the lens of the Arab world
por: Tharwat, Mina, et al.
Publicado: (2022)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
por: Boccatonda, Andrea, et al.
Publicado: (2023)

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change
por: Singh, Shivaram P, et al.
Publicado: (2022)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life
por: Attia, Dina, et al.
Publicado: (2022)

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
por: Lonardo, Amedeo
Publicado: (2021)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
por: Musio, Alessandra, et al.
Publicado: (2023)

Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
por: Park, So Hee, et al.
Publicado: (2023)

Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
por: Baratta, Francesco, et al.
Publicado: (2021)

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
por: Gatzios, Alexandra, et al.
Publicado: (2022)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations
por: Xu, Xin, et al.
Publicado: (2023)

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
por: Portincasa, Piero
Publicado: (2023)

Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States
por: Xie, Zhi-Qin, et al.
Publicado: (2022)

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
por: Chua, Damien, et al.
Publicado: (2022)

Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients
por: Ordoñez-Vázquez, Ana Luisa, et al.
Publicado: (2022)

Correction to: NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
por: Portincasa, Piero
Publicado: (2023)

MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
por: Xian, Ying-Xin, et al.
Publicado: (2021)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
por: Niriella, Madunil Anuk, et al.
Publicado: (2021)

Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females
por: Sogabe, Masahiro, et al.
Publicado: (2022)

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
por: Lonardo, Amedeo, et al.
Publicado: (2022)

Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
por: Vaz, Karl, et al.
Publicado: (2023)

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2022)

Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults
por: Peng, Hongye, et al.
Publicado: (2023)

Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study
por: Yu, Cheng, et al.
Publicado: (2022)

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science
por: Fouad, Yasser, et al.
Publicado: (2022)

Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study
por: Liu, Qingdan, et al.
Publicado: (2023)

Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index–related parameters
por: Xue, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_598peae9hfq9b6k4tq0993ppns